Topical corticosteroids

Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print

Volumn , Issue , 2012, Pages 487-504

  Warner, Michael R ^a   Camisa, Charles ^b,c  

^a The Cosmetic and Skin Surgery Center   (United States)

^b Riverchase Dermatology   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888592349     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2003-7.00040-6     Document Type: Chapter

References (210)

1. Stoughton RB Vasoconstriction activity and percutaneous absorption of glucocorticosteroids. Arch Dermatol 1969, 99:753-756.
2. Cornell RC, Stoughton RB Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985, 121:63-67.
3. Camisa C Corticosteroids. Psoriasis Second Edition 2004, 139-157. Blackwell Scientific, Boston. C. Camisa (Ed.).
4. Ponec M Glucocorticoids and cultured human skin cells: specific intracellular binding and structure-activity relationships. Br J Dermatol 1982, 107(Suppl 23):24-29.
5. Ponec M, Kenpenaar J, Shroot B, et al. Glucocorticoids: binding affinity and lipophilicity. J Pharm Sci 1986, 75:973-975.
6. Bikowski J, Pillai R.Shroot B The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol 2006, 5:125-130.
7. Phillips GH Locally active corticosteroids: structure-activity relationships. Mechanisms of topical corticosteroid activity 1976, 1. Churchill Livingstone, Edinburgh. L. Wilson, R. Marks (Eds.).
8. Kamm A The pharmacologic profile of clobetasol propionate: a new high potency steroid. Clobetasol: an investigator's report 1986, 10-18. Glaxo Monograph, Philadelphia.
9. Yohn JJ, Weston WL Topical glucocorticosteroids. Curr Probl Dermatol 1990, 2:38-63.
10. Stoughton RB, Cornell RC Topical steroids in dermatology. Topical corticosteroid therapy: a novel approach to safer drugs 1988, 1-12. Raven Press, New York. E. Christophers, E. Schopf, A.M. Kligman (Eds.).
11. Vickers CFH Existence of a reservoir in the stratum corneum. Arch Dermatol 1963, 88:20-23.
12. Purdon CH, Haigh JM, Surber C, et al. Foam drug delivery in Dermatology: Beyond the scalp. Am J Drug Deliv 2003, 1:71-75.
13. Clarys P, Gabard B, Barel AO A qualitative estimate of the influence of halcinonide concentration and urea on the reservoir formation in the stratum corneum. Skin Pharmacol Appl Skin Physiol 1999, 12:85-89.
14. Catt KJ, Dufau ML Hormone action: Control of target cell function by peptide, thyroid and steroid hormones. Endocrinology and metabolism 1981, 61-105. McGraw-Hill, New York. P. Felig, J.D. Baxter, A.E. Broadus (Eds.).
15. Thompson EB The structure of the human glucocorticoid receptor and its gene. J Steroid Biochem 1987, 27:105-108.
16. Lan NC, Karin M, Nguyen T, et al. Mechanisms of glucocorticoid hormone action. J Steroid Biochem 1984, 20:77-88.
17. Spindler SR, Mellon-Nussbaum S, Baxter JD Growth hormone gene transcription is regulated by thyroid and glucocorticoid hormones in cultured rat pituitary tumor cells. J Biol Chem 1982, 257:627-632.
18. Evans RM, Birnberg NC, Rosenfeld MG Glucocorticoid and thyroid hormones transcriptionally regulate growth hormone gene expression. Proc Natl Acad Sci USA 1982, 79:7659-7663.
19. Schäcke H, Berger M, Rehwinkel H, et al. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007, 275:109-117.
20. MacGregor RR Inhibition of granulocyte adherence: potential mechanism of action of anti-inflammatory drugs. Clin Res 1974, 22:423A.
21. Dale DC, Rauci AS, Wolff SM Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med 1974, 291:1154-1158.
22. Dale DC, Fauci AS, Guerry DIV, et al. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 1975, 56:808-813.
23. Rebuck JW, Mellinger RC Interruption by topical cortisone of leukocyte cycles in acute inflammation in man. Ann NY Acad Sci 1953, 56:715-732.
24. Balow JE, Rosenthal AS Glucocorticoid suppression of macrophage inhibitory factor. J Exp Med 1973, 137:1031-1041.
25. Weston WL, Claman HN, Krueger CG Site of action of cortisol in cellular immunity. J Immunol 1973, 110:880-883.
26. Rinehart JJ, Balcerzak SP, Sagone AL, et al. Effects of corticosteroids on human monocyte function. J Clin Invest 1974, 54:1337-1343.
27. Hattori T, Hirata F, Hoffman T, et al. Inhibition of human natural killer (NK) activity and antibody-dependent cellular cytotoxicity (ADCC) by lipomodulin, a phospholipase inhibitory protein. J Immunol 1983, 131:662-665.
28. Hoffman T, Hirata F, Bougnouz P, et al. Phospholipid methylation and phospholipase A2 activation in cytotoxicity by human natural killer cells. Proc Natl Acad Sci USA 1981, 78:3839-3843.
29. Hellewell PG, Williams TJL An anti-inflammatory steroid inhibits tissue sensitization by IgE in vivo. Br J Pharmacol 1989, 96:5-7.
30. Altura BM Role of glucocorticoids in local regulation of blood flow. Am J Physiol 1966, 211:1393-1397.
31. Guyre PM, Bodwell JE, Hollbrook NJ, et al. Glucocorticoids and the immune system: activation of glucocorticoid-receptor complexes in thymus cells; modulation of Fc receptors of phagocytic cells. Progress in research and clinical applications of corticosteroids 1981, 14-27. Heyden, Philadelphia. H.J. Lee, C.A. Walker (Eds.).
32. DiRosa M, Flower RJ, Hirata F, et al. Anti-phospholipase proteins. Prostaglandins 1984, 28:441-442.
33. Ramey ER, Goldstein MS The adrenal cortex and the sympathetic nervous system. Physiol Rev 1957, 37:155-195.
34. Fritz I, Levine R Action of adrenal cortical steroids and norepinephrine on vascular responses of stress in adrenalectomized rats. Am J Physiol 1951, 165:456-465.
35. Besse JC, Bass AD Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. J Pharmacol Exp Ther 1966, 154:224-238.
36. Kalsner S Steroid potentiation of responses to sympatho-mimetic amines in aortic strips. Br J Pharmacol 1969, 36:582-593.
37. Altura BM Role of glucocorticoids in local regulation of blood flow. Am J Physiol 1966, 211:1393-1397.
38. Marks R, Williams K The action of topical steroids on the epidermal cell cycle. Mechanisms of topical corticosteroid activity 1976, 39. Churchill Livingstone, Edinburgh. L. Wilson, R. Marks (Eds.).
39. Fisher LB, Maibach HI The effect of corticosteroids on epidermal mitotic activity. Arch Dermatol 1971, 103:39-44.
40. Lehman P, Zheng P, Lavker RM, et al. Corticosteroid atrophy in human skin. A study by light, scanning and transmission elecron microscopy. J Invest Dermatol 1983, 81:169-176.
41. Nissen JB, Avrach WW, Hansen ES, et al. Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment. Dermatology 1999, 198:11-17.
42. Oikarinen A, Peltonen L, Hintikka J, et al. A local potent glucocorticosteroid decreases the induction of galactosylhydroxylysl glucosyltransferase in suction blisters but has no effect on basement membrane structures. Br J Dermatol 1983, 108:171-178.
43. Hein R, Krieg T Effects of corticosteroids on human fibroblasts in vitro. Topical corticosteroid therapy: a novel approach to safer drugs 1988, 57-65. Raven Press, New York. E. Christophers, E. Schopf, A.M. Kligman (Eds.).
44. Saarni H Cortisol effects on the glycosaminoglycan synthesis and molecular weight distribution in vitro. Biochem Pharmacol 1978, 27:1029-1032.
45. Smith TJ Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones. J Clin Invest 1984, 74:2157-2163.
46. Rokowski RJ, Sheehy J, Cutroneo KR Glucocorticoid selective reduction of functioning collagen messenger ribonucleic acid. Arch Biochem Biophys 1981, 210:74-81.
47. Oikarinen J, Pihlajaniemi T, Hamalainen L, et al. Cortisol decreases the cellular concentration of translatable type-I procollagen mRNA species in cultured human skin fibroblasts. Biochem Biophys Acta 1983, 741:297-302.
48. Oikarinen A, Hannuksela M Effect of hydrocortisone-17-butyrate, hydrocortisone and clobetasol-17-propionate on prolyl hydroxylase activity in human skin. Arch Dermatol Res 1980, 267:79-82.
49. Benson SC, Lu Valle PA Inhibition of lysyl oxidase and prolyl hydroxylase activity in glucocorticoid treated rats. Biochem Biophys Res Commun 1981, 99:557-562.
50. Jeffrey JJ, Coffey RJ, Eisen AZ Studies on uterine collagenase in tissue culture, II: effect of steroid hormones on enzyme production. Biochem Biophys Acta 1971, 252:143-149.
51. Silbert JE Proteoglycans and glycosaminoglycans. Biochemistry and physiology of the skin 1983, 448-461. Oxford University Press, New York. L.A. Goldsmith (Ed.).
52. Marks R Survey of methods for assessment of corticosteroid atrophogenicity. Topical corticosteroid therapy: a novel approach to safer drugs 1988, 105-110. Raven Press, New York. E. Christophers, E. Schopf, A.M. Kligman (Eds.).
53. Bleehan SS, Chu AC, Hamann I, et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995, 133:592-597.
54. Faergemann J, Christenson O, Sjovall P, et al. An open label study of efficacy and safety of long term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2000, 14:393-396.
55. Hebert AA, Cook-Bolden FE, Basu S, et al. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol 2007, 6:175-181.
56. Dohil MA, Alvarez-Connelly E, Eichenfield LF Fluocinolone acetonide 0.01% in peanut oil: safety and efficacy data in the treatment of childhood atopic dermatitis in infants as yound as 3 months of age. Pediatr Dermatol 2009, 26:262-268.
57. Abramovits W, Oquendo M Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. Skinmed 2010, 8:72-79.
58. Eichenfield LF, Miller BH Two randomized, double-blind, placebo-controlled studies of fluticasone proprionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. J Am Acad Dermatol 2006, 54:715-717. Cutivate Lotion Study Group.
59. Thomas KS, Armstrong S, Avery A, et al. Randomized controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. Brit Med J 2002, 324:768.
60. Lebwohl M A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone. Int J Dermatol 1999, 38:604-606.
61. Wilson R, Camacho F, Clark AR, et al. Adherence to topical hydrocortisone 17-butyrate 0.1% in different vehicles in adults with atopic dermatitis. J Am Acad Dermatol 2009, 60:166-168.
62. Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004, 15:169-178.
63. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002, 205:271-277.
64. Jessop S, Whitelaw DA, Delamere FM Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009, (7). CD002954.
65. Madan V, August PJ, Chalmers RJ Efficacy of topical tacrolimus 0.3% in clobetasol proprionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol 2010, 35:27-30.
66. Muhlbauer JE Granuloma annulare. J Am Acad Dermatol 1980, 3:217.
67. Thongprasom K, Dthanuthai K Steroids in the treatment of lichen planus: a review. J Oral Sci 2008, 50:377-385.
68. Farhi D, Dupin N Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol 2010, 28:100-108.
69. Voute AB, Schulten EA, Langendijk PN, et al. Fluocinonide in an adhesive base for treatment of oral lichen planus. A double-blind, placebo-controlled clinical study. Oral Surg Oral Med Oral Patho 1993, 75:181-185.
70. Aquirre JM, Bagan JV, Rodriguez C, et al. Efficacy of mometasone furoate microemulsion in the treatment of erosive-ulcerative oral lichen planus: pilot study. J Oral Pathol Med 2004, 33:381-385.
71. Hegarty AM, Hodgeson TA, Lewsey JD, et al. Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. J Am Acad Dermatol 2002, 47:271-279.
72. Carbone M, Goss E, Carrozzo S, et al. Systemic and topical corticosteroid treatment of oral lichen planus: a comparative study with long-term follow-up. J Oral Pathol Med 2003, 32:323-329.
73. Carbone M, Conrotto D, Carrozzo M, et al. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Dis 1999, 5:44-49.
74. Cevasco NC, Bergfeld WF, Remzi BK, et al. A case series of 29 patients with lichen planopilaris: the Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol 2007, 57:47-53.
75. Pugliese JM, Morey AF, Peterson AC Lichen sclerosus: review of the literature and current recommendations for management. J Urol 2007, 178:2268-2276.
76. Cattani P, Manfrin E, Presti F, et al. Our experience in treating lichen sclerosus. Minerva Ginecol 1997, 49:207-212.
77. Fischer GO Lichen sclerosus in childhood. Aust J Dermatol 1995, 36:166-167.
78. Garzon MC, Paller AS Ultrapotent topical corticosteroid treatment of childhood genital lichen sclerosus. Arch Dermatol 1999, 135:525-528.
79. Sinha P, Sorinola O, Luesley DM Lichen sclerosus of the vulva. Long-term steroid maintenance therapy. J Reprod Med 1999, 44:621-624.
80. Dahlman-Ghozlan K, Hedblad MA, von Krogh G Penile lichen sclerosus et atrophicus treated with clobetasol dipropionate 0.05% cream: a retrospective clinical and histopathological study. J Am Acad Dermatol 1999, 40:451-457.
81. Ghysel C, Vander Eeckt K, Bogaert GA Long-term efficiency of skin stretching and a topical corticosteroid cream application for unretractable foreskin and phimosis in prepubertal boys. Urol Int 2009, 82:81-88.
82. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009, 60:643-659.
83. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009, (15). CD005028.
84. Menter A Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis 2007, 80:12-19.
85. Katz HI, Hien NT, Prauer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris - clinical efficacy and adrenal function. J Am Acad Dermatol 1987, 16:804-811.
86. Gammon WR, Krueger GG, Van Scott EJ, et al. Intermittent short courses of clobetasol propionate ointment 0.05% in the treatment of psoriasis. Curr Ther Res 1987, 42:419-427.
87. Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009, 60:120-124.
88. de Jager ME, de Jong EM, van de Kerkoff PC, et al. Efficay and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010, 62:1013-1030.
89. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009, 60:962-971.
90. Crowley J Scalp psoriasis: an overview of the disease and available therapies. J Drugs Dermatol 2010, 9:912-918.
91. Bovenschen HJ, Van de Kerkhof PC Treatment of scalp psoriasis with clobetasol-17 propionate 0.05% shampoo: a study on daily clinical practice. J Eur Acad Dermatol Venereol 2010, 24:439-444.
92. Claréus BW, Houwing R, Wigchert S The DESIRE study - psoriasis patients' satisfaction with topical treatment using a fixed combination of calcipotriol and betamethasone dipropionate in daily clinical practice. Eur J Dermatol 2009, 19:581-585.
93. Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomized, parallel group, double-blind, exploratory study. Eur J Dermatol 2010, 20:465-471.
94. van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, clinical trial. Br J Dermatol 2009, 160:170-176.
95. Menter A, Abramovits W, Coln, et al. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone diproprionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 2009, 8:52-57.
96. Lahfa M, Mrowietz U, Koening M, et al. A new regimen for the treatment of plaque psoriasis. Eur J Dermatol 2003, 13:261-265.
97. Feldman SR, Koo JY, Johnson LA, et al. Clobetasol propionate spray 0.05% add-on therapy to a stable regiment of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis 2009, 84:25-32.
98. Finzi AF Individualized short-course cyclosporin therapy in psoriasis. Br J Dermatol 1996, 135(Suppl 48):31-34.
99. Koo J, Cuffie CA, Tanner DJ, et al. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Therapeut 1998, 20:283-291.
100. Swinkels OQ, Prins M, Tosserams EF, et al. The influence of a topical corticosteroid on short-contact high-dose dithranol therapy. Br J Dermatol 2001, 145:63-69.
101. Sander P, Stucker M, Hermes N, et al. Mometasone and calcipotriol optimize the therapeutic effect of dithranol on chronic stationary psoriasis. Hautarzt 1998, 49:291-294.
102. Poulin YP Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 1999, 63:41-48.
103. Sánchez Regaa M, Márquez Balbás G, Umbert Millet P Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. J Eur Acad Dermatol Venereol 2008, 22:963-969.
104. Naseri M, Hadipour A, Sepaskhah M, et al. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med 2010, 19:58-61.
105. Kragballe K, Larsen FG A hydrocolloid occlusive dressing and triamcinolone acetonide cream is superior to clobetasol cream and in palmo-plantar psoriasis. Acta Derm Venereol 1991, 71:540-542.
106. David M, Lowe NJ Psoriasis therapy: comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol 1989, 21:511-512.
107. Krueger GG, O'Reilly MA, Weidner M, et al. Comparative efficacy of once-daily flurandrenolide tape versus twice-daily diflorasone diacetate ointment in the treatment of psoriasis. J Am Acad Dermatol 1998, 38:186-190.
108. Volden G Successful treatment of chronic skin disease with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992, 72:69-71.
109. Van der Vleuten CJ, van Vlijmen-Willems IM, de Jong EM, et al. Clobetasol-17-propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. Arch Dermatol Res 1999, 291:390-395.
110. Volden G, Kragballe K, Van de Kerkhof PC, et al. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatolog Treat 2001, 12:133.
111. Manriquez JJ, Uribe P Seborrheic dermatitis. Clin Evid (Online) 2007, Jul 1; 2007. pii: 1713.
112. Bikowski J Facial seborrheic dermatitis: a report on current status and therapeutic horizons. J Drugs Dermatol 2009, 8:125-133.
113. Chung CL, Cusack CA Wells syndrome: an enigmatic and therapeutically challenging disease. J Drugs Dermatol 2006, 5:908-911.
114. Camisa C, Rindler J Diseases of the oral mucous membranes. Curr Probl Dermatol 1996, 8:41-96.
115. Camisa C, Warner M Treatment of pemphigus. Dermatol Nursing 1998, 10:115-131.
116. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009, 129:1681-1687.
117. Spuls PI, Brakman M, Westerhof W, et al. Treatment of generalized bullous pemphigoid with topical corticosteroids (letter). Acta Derm Venereol 1995, 75:89.
118. Kjellman P, Eriksson H, Berg P A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008, 144:612-616.
119. Hornschuh B, Hamin H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol 1997, 36:101-103.
120. Thomas I, Khorenian S, Arbesfeld DM Treatment of generalized bullous pemphigoid with oral tetracycline. J Am Acad Dermatol 1993, 28:74-77.
121. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
122. Van Exel CE, English JC Erosive pustular dermatitis of the scalp and nonscalp. J Am Acad Dermatol 2007, 57:S11-S14.
123. Tavares-Bello R Erosive pustular dermatosis of the scalp. A chronic recalcitrant dermatosis developed upon CO2 laser treatment. Dermatology 2009, 219:71-72.
124. Mangelsdorf HC, White WL, Jorizzo JL Behçet's disease. Report of 25 patients from the United States with prominent mucocutaneous involvement. J Am Acad Dermatol 1996, 34:745-750.
125. Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010, 62:646.
126. Shah M, Lewis FM, Harrington CTR Scrotal pyoderma gangrenosum associated with dermatomyositis. Clin Exp Dermatol 1996, 21:151-153.
127. Delamere FM, Sladden MM, Dobbins HM, et al. Interventions for alopecia areata. Cochrane Database Syst Rev 2008, (16). CD004413.
128. Alkhalifah A, Alsantali A, Wang E, et al. Alopecia areata update: part II. Treatment. J Am Acad Dermatol 2010, 62:191-202.
129. Zackheim HS, Kashani-Sabet M, Amin S Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998, 134:949-954.
130. Zackheim HS Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther 2003, 16:283-287.
131. Kumari J Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984, 120:631-635.
132. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines for care for vitiligo. J Am Acad Dermatol 1996, 35:620-626.
133. Whitton ME, Ashcroft DM, Gonzalez U Therapeutic interventions for vitiligo. J Am Acad Dermatol 2008, 59:713-717.
134. Handa S, Pandhi R, Kaur I Vitiligo: a retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol 2001, 28:461-466.
135. Njoo MD, Westerhof W, Bos JD, et al. Development of guidelines for the treatment of vitiligo. Arch Dermatol 1999, 135:1514-1521.
136. Cockayne SE, Messenger AG, Gawkrodger DJ, et al. Vitiligo treated with topical corticosteroids: Children with head and neck involvement respond well. J Am Acad Dermatol 2002, 46:964-965.
137. Travis LB, Silverberg NB Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol 2004, 21:495-498.
138. Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis 2005, 75:57-62.
139. Grimes PE, Bhawan J, Guevara IL, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol 2010, 62:962-967.
140. Pandey A, Gangopadhyay AN, Sharma SP, et al. Evaluation of topical steroids in the treatment of superficial hemangioma. Skinmed 2010, 8:9-11.
141. Al-Ghnaniem R, Short K, Pullen A, et al. 1% hydrocortisone ointment is an effective treatment of pruritus ani: a pilot randomized controlled crossover trial. Int J Colorectal Dis 2007, 22:1463-1467.
142. Lyon CC, Smith AJ, Griffiths CEM, et al. Peristomal dermatoses: A novel indication for topical steroid lotions. J Am Acad Dermatol 2000, 43:679-682.
143. Munro DD. Percutaneous absorption in humans with particular reference to topical steroids and their systemic influence. Thesis for doctorate in medicine, University of London, 1975.
144. May P, Stein EJ, Ryter RJ, et al. Cushing syndrome from percutaneous absorption of triamcinolone cream. Arch Intern Med 1976, 136:612-613.
145. Himathongkam T, Dasanabhairochana P, Pitchayayothin N, et al. Florid Cushing's syndrome and hirsutism induced by desoximetasone. JAMA 1978, 239:430-431.
146. Gilbertson EO, Spellman MC, Piacquadio DJ, et al. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998, 38:318-321.
147. Brozyskowski M, Grant DB, Wells RS Cushing's syndrome induced by topical steroids used for the treatment of nonbullous icthyosiform erythroderma. Clin Exp Dermatol 1976, 1:337-342.
148. Keipert JA, Kelly R Temporary Cushing's syndrome from percutaneous absorption of betamethasone valerate. Med J Aust 1971, 1:542-544.
149. Bode HH Dwarfism following long-term topical corticosteroid treatment. JAMA 1980, 244:813-814.
150. Cook LJ, Freinkel RK, Zugerman C, et al. Iatrogenic hyperadrenocorticism during topical steroid therapy: assessment of systemic effects by metabolic criteria. J Am Acad Dermatol 1982, 6:1054-1060.
151. Carruthers JA, August PJ, Staughton RCD Observations on the systemic effect of topical clobetasol propionate (Dermovate). BMJ 1975, 4:203-204.
152. Ortega E, Burdick KH, Segre EJ Adrenal suppression by clobetasol propionate. Lancet 1975, 1:1200.
153. Haeck IM, Timmer-de Mik L, Lentjes EG, et al. Low basal serum cortisol in patients with severe atopic deramatitis: potent topical corticosteroids wrongfully accused. British J Dermatol 2007, 156:979-985.
154. West DP, Worobec S, Solomon LM Pharmacology and toxicology of infant skin. J Invest Dermatol 1981, 76:147-150.
155. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol 1996, 35:615-619.
156. Cunliffe WJ, Burton JL, Holti G, et al. Hazards of steroid therapy in hepatic failure. Br J Dermatol 1975, 93:183-185.
157. Fleming C, Ganslandt C, Leese GP Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. J Drugs Dermatol 2010, 9:969-974.
158. Abromovits W, Oquendo M Hydrocortisone butyrate 0.1% cream (proprietary lipid rich cream vehicle) does not significantly suppress hypothalamic-pituitary-adrenal axis and is effective in pediatric patients 3 months and older with extensive atopic dermatitis. Skinmed 2010, 8:150-154.
159. Eichenfield LF, Basu S, Calvarese B, et al. Effect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatric Dermatol 2007, 24:289-295.
160. Hebert AA, Friedlander SF, Allen DB Topical fluticasone propionate lotion does not cause HPA axis suppression. J Pediatr 2006, 149:378-382.
161. Chi CC, Kirtschig G, Gabbud JP, et al. Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol 2011, Jul 5. doi: 10.1111/j. 1365-2133.2011.10513.x. [Epub ahead of print].
162. Chi CC, Mayon-White RT, Wojnarowska FT Safety of topical corticosteroids in pregnancy: a population-based cohort study. J Invest Dermatol 2011, 131:884-891.
163. Akers WA Risks of unoccluded topical steroids in clinical trials. Arch Dermatol 1980, 116:786-788.
164. Kligman AM Adverse effects of topical corticosteroids. Topical corticosteroid therapy: a novel approach to safer drugs 1988, 181-187. Raven Press, New York. E. Christophers, E. Schopf, A.M. Kligman (Eds.).
165. Kirby JD, Munro DD Steroid-induced atrophy in an animal and human model. Br J Dermatol 1976, 94(Suppl 12):111-119.
166. Katz HI, Prawer SE, Mooney JJ, et al. Preatrophy: covert sign of thinned skin. J Am Acad Dermatol 1989, 20:731-735.
167. Feldman RJ, Maibach HI Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967, 48:181-183.
168. Johns AM, Bower BD Wasting of the napkin area after repeated use of fluorinated steroid ointment. BMJ 1970, 1:347-348.
169. O'Donoghue MN Perioral dermatitis. Cutaneous medicine and surgery 1996, 497-502. WB Saunders, Philadelphia. K.A. Arndt, P.E. Leboit, J.K. Robinson (Eds.).
170. Rapaport MJ, Rapaport V Eyelid dermatitis to red face syndrome to cure: Clinical experience in 100 cases. J Am Acad Dermatol 1999, 41:435-442.
171. Fulton JE, Kligman AM Aggravation of acne vulgaris by topical application of corticosteroids under occlusion. Cutis 1968, 4:1106-1109.
172. Leyden JJ, Thew M, Kligman AM Steroid rosacea. Arch Dermatol 1974, 110:619-622.
173. MacMillan AL Unusual features of scabies associated with topical fluorinated steroids. Br J Dermatol 1972, 87:497.
174. Ive FA, Marks R Tinea incognito. BMJ 1968, 3:149-152.
175. Harlan SL Streroid acne and rebound phenomenon. J Drugs in Dermatol 2008, 7:547-550.
176. Wilson FM Adverse external ocular effects of topical ophthalmic medications. Surg Ophthalmol 1979, 24:57-88.
177. Haeck IM, Rouwen TJ, Timmer-de Mik L, et al. Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol 2011, 64:275-281.
178. Aggarwa RK, Potamitis T, Chong NHV, et al. Extensive visual loss with topical facial steroids. Eye 1993, 7:664-666.
179. Schwartzenberg GWS, Buys Y Glaucoma secondary to topical use of steroid cream. Can J Ophthalmol 1999, 34:222-225.
180. Pratt MD, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch-test results, 2001-2002 study period. Dermatitis 2004, 176-183.
181. Marléne I, Magnus B Contact allergen of the year: corticosteroids. Dermatitis 2005, 16:3-5.
182. Hayakawa R, Matsunaga K, Suzuki M, et al. Allergic contact dermatitis due to budesonide. Contact Dermatitis 1991, 24:136-137.
183. Stingeni L, Caraffin S, Assalve D, et al. EM-like contact dermatitis from budesonide. Contact Dermatitis 1996, 34:154-155.
184. Miranda-Romero A, Sánchez-Sambucety P, Bajo C, et al. Genital edema from contact allergy to prednicarbate. Contact Dermatitis 1994, 30:41-44.
185. Marléne I Corticosteroids. Dermatol Ther 2004, 17:314-320.
186. Jacob SE, Steele T Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol 2006, 54:723-727.
187. Scheuer E, Warshaw E Allergy to corticosteroids: update and review of epidemiology, clinical characteristics, and structureal cross-reactivity. Am J Contact Dermatitis 2003, 14:179-187.
188. Bircher AJ, Levy F, Langauer S, et al. Contact allergy to topical corticosteroids and systemic contact dermatitis from prednisolone with tolerance of triamcinolone. Acta Derm Venereol 1995, 75:490-493.
189. Du Vivier A, Stoughton RB Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975, 3:581-583.
190. DuVivier A Tachyphylaxis to topically applied steroids. Arch Dermatol 1976, 112:1245-1248.
191. DuVivier A, Stoughton RB Acute tolerance to effects of topical glucocorticosteroids. Br J Dermatol 1976, 94(Suppl 12):25-32.
192. Du Vivier A, Phillips H, Hehir M Applications of glucocorticosteroids. Arch Dermatol 1982, 118:305-308.
193. Singh G, Gupta A, Pandey SS, et al. Tachyphylaxis to histamine-induced wheal suppression by topical 0.05% clobetasol propionate in normal versus croton oil-induced dermatitic skin. Dermatology 1996, 193:121-123.
194. Miller JJ, Roling D, Margolis D, et al. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 1999, 41:546-549.
195. Feldman SR Tachyphylaxis to topical corticosteroids: the more you use them, the less they work?. Clin Dermatol 2006, 24:229-230.
196. Marliere V, Roul S, Labreze C, et al. Crusted (Norwegian) scabies induced by use of topical corticosteroids and treated successfully with ivermectin. J Pediatr 1999, 135:122-124.
197. Perez E, Barnadas MA, Garcia-Patos V, et al. Kaposi's sarcoma in a patient with erythroblastopenia and thymoma: reactivation after topical corticosteroids. Dermatology 1998, 197:264-267.
198. Warner M, Taylor J Agents causing contact urticaria. Clin Dermatol 1997, 15:623-635.
199. Coloe J, Zirwas MJ Allergens in corticosteroid vehicles. Dermatititis 2008, 19:38-42.
200. Stoughton RB Are generic formulations equivalent to trade name topical glucocorticoids?. Arch Dermatol 1987, 123:1312-1314.
201. Olsen EA A double blind controlled comparison of generic and trade name topical steroids using the vasoconstriction assay. Arch Dermatol 1991, 127:197-201.
202. Jackson DB, Thompson C, McCormack JR, et al. Bioequivalence (bioavailability) of generic topical corticosteroids. J Am Acad Dermatol 1989, 20:791-796.
203. Stoughton TB, Wullich K The same glucocorticoid in brand-name products. Arch Dermatol 1989, 125:1509-1511.
204. Green C, Colquitt JL, Kirby J Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systemic review and economic evaluation. Health Technol Assess 2004, 8:1-120.
205. Green C, Colquitt JL, Kirby J, et al. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol 2005, 152:130-141.
206. Epstein E Is tacrolimus more cost-effective than high potency corticosteroids are in the treatment of atopic dermatitis?. J Am Acad Dermatol 2004, 51:670-671.
207. Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003, 48:553-563.
208. Long CC, Finlay AY The fingertip unit - a new practical measure. Clin Exp Dermatol 1991, 16:444-447.
209. Timmins P, Gray EA Degradation of hydrocortisone in a zinc oxide lotion. J Clin Hosp Pharm 1983, 8:79-85.
210. Krochmal L, Wang JCT, Patel B, et al. Topical corticosteroid compounding: effects on physiochemical stability and skin penetration rate. J Am Acad Dermatol 1989, 21:979-984.